Vertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $2.51, $0.08 worse than the analyst estimate of $2.59. Revenue for the quarter came in at $1.63 billion versus the consensus estimate of $1.58 billion.

"Our achievements in 2020 were marked by a significant increase in the number of people treated with the triple combination in the U.S. and the EU. It was also a year marked by meaningful pipeline advancement. We now have clinical programs in seven disease areas, spanning multiple modalities including small molecules for alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases, gene editing for sickle cell disease and beta thalassemia, and cell therapy for type 1 diabetes,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. "As we enter 2021, we look forward to treating more CF patients and reaching important R&D milestones in multiple additional diseases which will fuel our growth this year and for many years to come."

GUIDANCE:

Vertex Pharma sees FY2021 revenue of $6.7-6.9 billion, versus the consensus of $6.95 billion.

For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.